ResMed (RMD) Financial History
Review ResMed annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2009 through FY2026.
Financials
18 fiscal years, FY2009 to FY2026
Insider trades
377 trades
Risk factor changes
8 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
ResMed Financial Statements
History since FY2009. Annual, in US dollars. Source: 10-K XBRL data.
ResMed Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
ResMed Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
ResMed Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
ResMed Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
ResMed Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 🔒 | FY2022 | FY2023 | FY2024 | FY20252 new risk factorsInsiders net sold $56.6M | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | +18.0% | +10.9% | +9.8% | +9.9% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $2.0B | $2.4B | $2.7B | $3.1B | $3.5B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $1.0B | $1.1B | $1.3B | $1.7B | $1.9B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.8B | $0.9B | $1.0B | $1.4B | $1.5B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.8B | $1.4B | $0.7B | $0.7B | $0.7B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.2B | $0.6B | $1.3B | $1.7B | $1.6B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 39.6× | 35.9× | 27.7× | 27.1× | 18.7× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 9.1× | 7.8× | 5.8× | 6.3× | 4.3× |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $258.69 | $211.34 | $171.22 | $230.03 | $241.87 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $208.14 | $172.03 | $228.69 | $240.91 | $238.83 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $262.29 | $243.40 | $260.49 | $293.77 | $277.67 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $189.48 | $132.24 | $164.18 | $198.95 | $180.50 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | -20.1% | -17.3% | +32.9% | +5.3% | -0.9% |
ResMed Insider Transactions
From Form 4 filings. Showing the latest 5 of 377 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-10-23 | 2026-10-26 | Michael Rider General Counsel | Sold | 400 | $102K at ~$255 | 3% |
| 2026-10-07 | 2026-10-08 | Michael Farrell CEO | Option exercise (2 trades) | 9,982 | $730K | — |
| 2026-10-07 | 2026-10-08 | Michael Farrell CEO | Sold | 4,991 | $1.1M at ~$226 | 1% |
| 2026-08-14 | 2026-10-01 | Justin Leong Chief Product Officer | Grant or award | 6,461 | — | — |
| 2026-08-14 | 2026-10-01 | Michael Rider General Counsel | Grant or award | 3,230 | — | — |
ResMed Risk Factor Changes
Latest 10-K compared with the year before. 8 changes found.
Laws regulating consumer contacts could adversely affect our business operations or create liabilities.
Off-label marketing of our products could result in substantial penalties.
Disruptions at the FDA and other government agencies caused by funding shortages, personnel reductions, or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel…
system requirements of ISO 13485:2016.
On July 4, 2025, President Trump signed the budget reconciliation bill (entitled “One Big Beautiful Bill Act”, referred to herein as the “Bill”) to meet spending targets aimed at funding the Trump Administration’s dom…
On June 9, 2025, CMS finalized a National Coverage Determination (NCD) entitled “Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chron…
In 2022, the VA proposed an adjustment through regulation to amend the previously adopted schedule of VA ratings for sleep apnea.
Other federal legislative changes have been proposed and adopted since the ACA was enacted.
ResMed SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Quarterly report (10-Q) | 2026-10-30 | Quarter ended Sep 30, 2026 | View document |
| Current report (8-K) | 2026-10-29 | Quarterly results, Other news | View document |
| Proxy statement | 2026-10-01 | Shareholder meeting materials | View document |
| Current report (8-K) | 2026-09-01 | Other news | View document |
| Current report (8-K) | 2026-08-17 | Auditor change, Executive change | View document |
ResMed financial metrics by year
ResMed in the S&P 500 rankings
- #66 by net profit margin as of FY2026
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.
Compare ResMed with similar companies
- RMD vs BAX Baxter International
- RMD vs BDX Becton Dickinson
- RMD vs BSX Boston Scientific
- RMD vs DXCM Dexcom
- RMD vs MMM 3M
- RMD vs PODD Insulet
- RMD vs SOLV Solventum
- RMD vs SYK Stryker
- RMD vs WST West Pharmaceutical Services